MedTrace Logo

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

NCT05998642 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-14

No results posted yet for this study

Summary

This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading?

This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).

Conditions

Interventions

DRUG

Methotrexate

3.5mg/m2 IV

DRUG

Rituximab (where available)

375mg/m2 / 1400mg IV or SC

DRUG

Ibrutinib

Dose and schedule assigned at enrollment

Sponsors & Collaborators

  • Janssen Inc.

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Jean-Francois Larouche · CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, QC Canada

  • Anca Prica · University Health Network-Princess Margaret Hospital, Toronto, ON Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-13
Primary Completion
2028-05-31
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05998642 on ClinicalTrials.gov